• Wed news: BioNTech buying Biotheus. FDA’s Califf lists hopes for his successor. Amgen loses $12B market cap from hidden spreadsheet tab. TRex Bio raises $84M. London is Europe’s life science capitol. See more on our front page

ASH: J&J's Darzalex cuts death risk by 40% in new myeloma patients

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Dec 09, 2019 at 11:32: PM
via Johnson & Johnson hasn’t had problems convincing physicians to use multiple myeloma med Darzalex, which quickly went blockbuster and beyond on the back of some historic approvals. But new "gold standard" data presented Monday could further increase doctors’ confidence in the med, the company says.

article source
 




Top Bottom
Back
Quote